UNSPSC 51171944: Irsogladine

This classification denotes an anti-ulcer agent with the molecular formula C9H7Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QBX79NZC1D, chemically known as 1,3,5-triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- but generally known as irsogladine, which bears US NIH Compound Identifier 3752. European Medicines Agency schedules Irsogladine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08299MIG. The term IRSOGLADINE is an International Non-Proprietary Name.

UNSPSC 51171944 Irsogladine, a Commodity code, represents pharmaceutical products that state and local governments procure through both direct-service contracts and cooperative purchasing vehicles. Recent solicitations show that state and local buyers source irsogladine and similar pharmaceuticals as part of broader drug testing, pharmacy benefit, and generic pharmaceutical procurement programs rather than as standalone product lines. The code appears in three distinct procurement contexts: offender drug testing programs that require specific pharmaceutical screening and confirmation methodologies, state pharmacy benefit initiatives exploring direct-to-manufacturer supply chains, and multi-state cooperative pharmaceutical purchasing agreements serving government health facilities and employee groups.

Issuing bodies include county criminal justice departments (Collin County Community Supervision and Corrections Department), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering agreements on behalf of Minnesota Department of Administration and participating states including Oregon). Collin County's RFP 2026-327, posted July 9, 2026 with response due July 23, 2026, seeks offender specimen collection and drug testing services with an estimated annual volume of 25,031 tests and contract value of $600,000 over two years with optional three-year renewals, requiring vendors to maintain SAMHSA, Texas DPS, or CAP lab certification. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs. Activity concentrates in Texas and Minnesota, with geographic spread extending to Oregon through cooperative purchasing.